JB Chemicals & Pharmaceuticals Ltd. (JBCHEPHARM) AI Stock Analysis

• Market Cap: ₹260.18B
• Dividend Yield: 0.93%
• Average Volume (3M): 1.55K
• Price to Earnings (P/E): 37.7
• Beta (1Y): 0.54
• Revenue Growth: 11.56%
• EPS Growth: 16.30%
• Country: IN
• Employees: 5,311
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 13.70
• Shares Outstanding: 156,596,240
• 10 Day Avg. Volume: 1,708
• 30 Day Avg. Volume: 1,551
• PEG Ratio: 1.96
• Price to Book (P/B): 7.17
• Price to Sales (P/S): 6.28
• P/FCF Ratio: 30.57
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,824.00
• Price Target Upside: 9.78% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 66 Neutral
• Price Target: ₹1,824.00 ▲(9.78% Upside)

JB Chemicals & Pharmaceuticals Ltd. has a strong financial foundation with impressive revenue growth and profitability. However, technical indicators suggest a bearish trend, and the stock's high valuation may limit upside potential. The absence of earnings call and corporate events data means these factors do not influence the score.

JB Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients in India and internationally. Its principal products include Cilnidipine, Ranitidine, and Metronidazole. The company also provides contract manufacturing services for tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners. Further, the company provides its services in gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is based in Mumbai, India.

How the Company Makes Money

JB Chemicals & Pharmaceuticals Ltd. generates revenue primarily through the sale of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company's revenue streams include domestic and international sales of branded and generic pharmaceutical products. In the domestic market, JBCHEPHARM's revenue is driven by its strong portfolio of brands in key therapeutic areas, with significant contributions from its cardiovascular and gastrointestinal products. Internationally, the company earns from exporting its formulations and APIs to various markets, leveraging its global distribution network. Additionally, JBCHEPHARM may engage in strategic partnerships and collaborations that contribute to its earnings, such as licensing agreements or co-marketing initiatives with other pharmaceutical companies.

JB Chemicals & Pharmaceuticals Ltd. Financial Statement Overview

Summary

JB Chemicals & Pharmaceuticals Ltd. demonstrates strong financial performance with robust revenue growth, efficient cost management, and solid profitability metrics. The balance sheet is stable with low leverage, and cash flows are strong, though capital expenditure management requires attention.

Income Statement

JB Chemicals & Pharmaceuticals Ltd. has demonstrated strong revenue growth with a notable increase in total revenue from INR 24.2 billion to INR 39.2 billion in the latest annual period. The gross profit margin is impressive, reflecting efficient cost management, and the net profit margin has improved, indicating enhanced profitability. The EBIT and EBITDA margins also show a positive trajectory, supporting the company's stable financial performance.

Balance Sheet

The company's balance sheet is solid with a low debt-to-equity ratio, showcasing financial stability and low leverage risk. The return on equity is commendable, reflecting effective utilization of shareholder funds. The equity ratio is strong, indicating a healthy proportion of assets financed by equity. Overall, the balance sheet reflects financial robustness with moderate risk.

Cash Flow

JB Chemicals & Pharmaceuticals Ltd. exhibits a strong operating cash flow relative to net income, highlighting efficient cash generation from operations. The free cash flow has grown significantly, which bodes well for future investments and shareholder returns. However, fluctuations in capital expenditures could pose potential risks to sustaining cash flow growth.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	40.08B	39.18B	34.84B	31.17B	24.24B	20.06B
Gross Profit	22.34B	26.01B	13.46B	11.14B	15.61B	12.88B
EBITDA	10.81B	10.32B	9.33B	7.04B	5.82B	6.72B
Net Income	6.85B	6.60B	5.53B	4.10B	3.85B	4.48B
Balance Sheet
Total Assets	0.00	42.74B	39.94B	35.54B	26.07B	22.38B
Cash, Cash Equivalents and Short-Term Investments	4.50B	4.50B	4.60B	2.69B	566.50M	6.94B
Total Debt	0.00	278.90M	3.78B	5.72B	545.59M	449.88M
Total Liabilities	-34.33B	8.40B	10.71B	10.74B	4.69B	4.25B
Stockholders Equity	34.33B	34.33B	29.23B	24.80B	21.34B	18.10B
Cash Flow
Free Cash Flow	0.00	8.05B	5.39B	-1.39B	-5.37B	2.67B
Operating Cash Flow	0.00	9.02B	8.01B	6.26B	1.70B	3.15B
Investing Cash Flow	0.00	-2.96B	-4.08B	-9.62B	23.20M	-2.31B
Financing Cash Flow	0.00	-5.80B	-3.41B	3.57B	-1.38B	-874.23M

JB Chemicals & Pharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1661.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JBCHEPHARM, the sentiment is Negative. The current price of 1661.5 is below the 20-day moving average (MA) of 1697.40, below the 50-day MA of 1711.16, and below the 200-day MA of 1682.44, indicating a bearish trend. The MACD of -8.83 indicates Positive momentum. The RSI at 39.60 is Neutral, neither overbought nor oversold. The STOCH value of 39.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JBCHEPHARM.

JB Chemicals & Pharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AJANTPHARM	72 Outperform	₹303.76B	32.66	―	2.25%	10.92%	9.76%
GLAND	69 Neutral	₹319.55B	41.77	―	0.93%	-2.34%	6.64%
PFIZER	69 Neutral	₹238.83B	29.54	―	0.67%	4.35%	32.89%
JBCHEPHARM	66 Neutral	₹260.18B	37.74	―	0.93%	11.56%	16.30%
GLENMARK	54 Neutral	₹556.27B	74.09	―	0.13%	10.99%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

JB Chemicals & Pharmaceuticals Ltd. Corporate Events

JB Chemicals Announces Director Cessation

JB Chemicals & Pharmaceuticals Ltd. announced the cessation of Ms. Padmini Khare Kaicker as a Non-Executive Independent Director, effective August 30, 2025, following the completion of her five-year term. This change reflects the company’s adherence to regulatory requirements and governance practices, potentially impacting its board dynamics and strategic direction.

JB Chemicals & Pharmaceuticals Releases Q1 FY ’26 Earnings Call Transcript

JB Chemicals & Pharmaceuticals Ltd. has released the transcript of its Q1 FY ’26 earnings conference call, held on July 31, 2025, for investors and analysts. The call, which discussed the company’s financial results and strategic developments for the first quarter ending June 30, 2025, is available on the company’s website. The release of this transcript is part of the company’s ongoing efforts to maintain transparency and keep stakeholders informed about its financial performance and strategic direction.

JB Chemicals Announces Trading Window Closure

JB Chemicals & Pharmaceuticals Ltd. has announced the closure of its trading window from June 30, 2025, until 48 hours after the release of its unaudited financial results for the quarter ending June 30, 2025. This move is in compliance with SEBI regulations to prevent insider trading, ensuring transparency and fairness in the market.